Deutsch English Français

Contact

EP3749756

European procedure

Quick help

Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...

News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...

Extract from the Register of European Patents

EP About this file: EP3749756

EP3749756 - TRANSCRIPTION REGULATORY ELEMENTS AND USES THEREOF [Right-click to bookmark this link]
Status	Request for examination was made Status updated on 13.11.2020 Database last updated on 22.08.2024
Former	The international publication has been made Status updated on 10.08.2019
Most recent event Tooltip	27.02.2024	New entry: Renewal fee paid
Applicant(s)	For all designated states Audentes Therapeutics, Inc. 600 California Street 17th Floor San Francisco, CA 94108 / US
	[2020/51]
Inventor(s)	01 / GRAY, John T. 101 Montgomery Street Suite 2650 San Francisco, CA 94104 / US
	[2020/51]
Representative(s)	Hoffmann Eitle Patent- und Rechtsanwälte PartmbB Arabellastraße 30 81925 München / DE
	[2020/51]
Application number, filing date	19748361.3	05.02.2019
	[2020/51]
	WO2019US16692
Priority number, date	US201862626561P	05.02.2018 Original published format: US 201862626561 P
	[2020/51]
Filing language	EN
Procedural language	EN
Publication	Type:	A1 Application with search report
	No.:	WO2019153009
	Date:	08.08.2019
	Language:	EN
	[2019/32]
	Type:	A1 Application with search report
	No.:	EP3749756
	Date:	16.12.2020
	Language:	EN
	The application published by WIPO in one of the EPO official languages on 08.08.2019 takes the place of the publication of the European patent application.
	[2020/51]
Search report(s)	International search report - published on:	US	08.08.2019
	(Supplementary) European search report - dispatched on:	EP	08.11.2021
Classification	IPC:	C12N7/00, C12N15/86, C12Q1/70	[2020/51]
	CPC:	C12N15/86 (EP,US); A61K48/0058 (EP,US); A61K48/005 (EP); A61P3/00 (US); C12N7/00 (US); C12N2750/14143 (EP,US); (+) C12N2830/008 (EP,US); C12N9/2402 (EP) (-)
Designated contracting states	AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2020/51]
Extension states	BA	17.08.2020
	ME	17.08.2020
Validation states	KH	17.08.2020
	MA	17.08.2020
	MD	17.08.2020
	TN	17.08.2020
Title	German:	TRANSKRIPTIONSREGULIERENDE ELEMENTE UND VERWENDUNGEN DAVON	[2020/51]
	English:	TRANSCRIPTION REGULATORY ELEMENTS AND USES THEREOF	[2020/51]
	French:	ÉLÉMENTS DE RÉGULATION DE LA TRANSCRIPTION ET UTILISATIONS ASSOCIÉES	[2020/51]
Entry into regional phase	17.08.2020	National basic fee paid
	17.08.2020	Search fee paid
	17.08.2020	Designation fee(s) paid
	17.08.2020	Examination fee paid
Examination procedure	17.08.2020	Examination requested [2020/51]
	29.06.2022	Despatch of communication that the application is deemed to be withdrawn, reason: reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report not received in time
	08.09.2022	Amendment by applicant (claims and/or description)
Request for further processing for:	The application is deemed to be withdrawn due to failure to reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report/Supplementary European search report
	08.09.2022	Request for further processing filed
	08.09.2022	Full payment received (date of receipt of payment) Request granted
	19.09.2022	Decision despatched
Fees paid	Renewal fee
	25.02.2021	Renewal fee patent year 03
	25.02.2022	Renewal fee patent year 04
	27.02.2023	Renewal fee patent year 05
	27.02.2024	Renewal fee patent year 06
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:	Search	[A]WO02095006 (GENZYME CORP [US], et al) [A] 1-15 * claim 1 *;
		[A]WO2015196179 (UNIV FLORIDA [US]) [A] 1-15 * page 17, line 24 - page 20, line 29; example 1; claims 1-41 *;
		[A] - DOERFLER PHILLIP A ET AL, "Copackaged AAV9 Vectors Promote Simultaneous Immune Tolerance and Phenotypic Correction of Pompe Disease", RVSV(M DELTA 51)-M3 IS AN EFFECTIVE AND SAFE ONCOLYTIC VIRUS FOR CANCER THERAPY,, (20160101), vol. 27, no. 1, doi:10.1089/HUM.2015.103, ISSN 1557-7422, pages 43 - 59, XP002767258 [A] 1-15 * page 48, column l, paragraph 1 - page 54, column l, paragraph 1 * DOI: http://dx.doi.org/10.1089/hum.2015.103
	International search	[A]US2007161031 (TRINKLEIN NATHAN D [US], et al) [A] 49-52, 55-60* ; paragraph [0008] *;
		[Y]US2010120152 (WOODDELL CHRISTINE I [US], et al) [Y] 4/1-3, 5/4/1-3, 6/5/4/1-3, 7/6/5/4/1-3, 8/1-3, 9/8/1-3, 10/9/8/1-3, 11/10/9/8/1-3, 12/1-3, 13/12/1-3, 14/13/12/1-3, 15/14/13/12/1-3 * ; paragraph [0060] *;
		[Y]US2017218395 (BYRNE BARRY JOHN [US], et al) [Y] 1-3, 4/1-3, 5/4/1-3, 6/5/4/1-3, 7/6/5/4/1-3, 8/1-3, 9/8/1-3, 10/9/8/1-3, 11/10/9/8/1-3, 12/1-3, 13/12/1-3, 14/13/12/1-3, 15/14/13/12/1-3, 53-54 * ; paragraphs [0077], [0079], [0124] *;
		[Y]US2017275649 (VANDENDRIESSCHE THIERRY [BE], et al) [Y] 1-3, 4/1-3, 5/4/1-3, 6/5/4/1-3, 7/6/5/4/1-3, 8/1-3, 9/8/1-3, 10/9/8/1-3, 11/10/9/8/1-3, 12/1-3, 13/12/1-3, 14/13/12/1-3, 15/14/13/12/1-3, 53-54 * ; paragraphs figure 20; [0012], [0024], [0027], [0029], [0090], [0156] *

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.

Legal notice
Terms of use
24.2.25; 34p